FOLH1 and prostate cancer: The developed nanoparticles show promise for the treatment of prostate cancer and additional work is ongoing to target the nanoparticles to prostate specific membrane antigen overexpressed on cancer cells and to evaluate the therapeutic potential in animal models of prostate cancer.